<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106517</url>
  </required_header>
  <id_info>
    <org_study_id>ShenzhenPH spine wang04</org_study_id>
    <nct_id>NCT05106517</nct_id>
  </id_info>
  <brief_title>Desomumab vs Zoledronic Acid and Osteoporotic Compression Fracture</brief_title>
  <official_title>Attending Physician of Shenzhen People's Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone mineral density and function at 1 year after screw fixation with desomumab vs zoldronic&#xD;
      acid for osteoporotic vertebral compression fractures: a parallel double-blind randomized&#xD;
      controlled clinical trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conduct a single-center, double-blind, randomized controlled clinical trial according to&#xD;
      clinical Trial Reporting Standards (CONSORT). Bone mineral density and function of&#xD;
      osteoporotic vertebral compression fracture (OVCF) were compared 1 year after screw internal&#xD;
      fixation with desomumab vs zoledronic acid in Shenzhen People's Hospital from September, 2021&#xD;
      to November, 2022. The study was approved by Shenzhen People's Hospital and informed consent&#xD;
      was signed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">October 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>age</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sex</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants sex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>height</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants height cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants body mass index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum osteocalcin</measure>
    <time_frame>up to 12 months</time_frame>
    <description>osteocalcin in the N terminal molecular fracgment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum P1NP</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Procollagen type 1 n-terminal propeptide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum CTX</measure>
    <time_frame>up to 12 months</time_frame>
    <description>C-terminal cross-linked type 1 collagen terminal peptide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum total calcium</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum total calcium level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum PTH</measure>
    <time_frame>up to 12 months</time_frame>
    <description>serum parathyroid hormone level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum total phosphorus level</measure>
    <time_frame>up to 12 months</time_frame>
    <description>serum total phosphorus level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum tALP</measure>
    <time_frame>up to 12 months</time_frame>
    <description>serum total alkaline phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum Albumin</measure>
    <time_frame>up to 12 months</time_frame>
    <description>serum albumin level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lumber spine bone mineral density</measure>
    <time_frame>up to 12 months</time_frame>
    <description>DEXA for lumber spine bone mineral density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hip bone mineral density</measure>
    <time_frame>up to 12 months</time_frame>
    <description>DEXA for hip bone mineral density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI for lumber</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Bone marrow edema and adjacent intervertebral disc were detected by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The NRS is a segmented numerical version of the VAS in which a respondent selects a whole number (0- 10) that best reflects the intensity of the pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Rating Scales (VRS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>VRS use categories to differentiate pain intensity. There is a wide variability of terms used to describe each category and the rating may be divided into four (0 -3) or six (0 -5) categories. Patients score their pain intensity from absent (0) to severe (3) or from none (0) to very severe (5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Roland-Morris Disability Questionnaire</measure>
    <time_frame>up to 12 month</time_frame>
    <description>The RDQ is a health status measure designed to be completed by patients to assess physical disability due to low back pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QUALEFFO-31</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) was developed in 1997 to evaluate HRQoL for patients with osteoporosis. The questionnaire assesses quality of life in the aspect of pain, physical function, social function, general health, and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5D (EQ-5D)</measure>
    <time_frame>up to 12 month</time_frame>
    <description>EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Denosumab vs Zoledronate</condition>
  <arm_group>
    <arm_group_label>dnosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desomumab 60mg/6 months subcutaneously + placebo intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous zoledronic acid and placebo /6 months subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Desomumab 60mg/6 months subcutaneously + placebo iv</description>
    <arm_group_label>dnosumab</arm_group_label>
    <other_name>Denosumab 6 month/subcutaneous</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Iv zoledronic acid and placebo /6 months subcutaneously</description>
    <arm_group_label>zoledronic acid</arm_group_label>
    <other_name>Zoledronic acid intravenous once a year</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be age between 40 and 90 years old&#xD;
&#xD;
          -  X-ray diagnosis of 1-2 vertebral compression fractures&#xD;
&#xD;
          -  DEXA test BMD T value was less than -1&#xD;
&#xD;
          -  fracture history lasted within 6 weeks&#xD;
&#xD;
          -  Must be MRI showed bone marrow edema of injured segment&#xD;
&#xD;
          -  Must be lower back pain, local spines tenderness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must be able to have no posterior vertebral wall fracture&#xD;
&#xD;
          -  Must be able to have no patients with intervertebral fissure&#xD;
&#xD;
          -  Must be able to have no infection&#xD;
&#xD;
          -  Must be able to have no malignancy&#xD;
&#xD;
          -  Must be able to have no neurological dysfunction&#xD;
&#xD;
          -  Must be able to have no calcium level â‰¤2.13 mmol/L&#xD;
&#xD;
          -  Must be able to have no previous use of anti-osteoporosis drugs&#xD;
&#xD;
          -  Must be able to have no inability to perform magnetic resonance imaging&#xD;
&#xD;
          -  Must be able to have no prior back surgery&#xD;
&#xD;
          -  Must be able to have no other established contraindications for elective surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongyu Wang, Doctor</last_name>
    <phone>18241651300</phone>
    <email>wanghongyu790039663@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ShenzhenPH</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Wang, Doctor</last_name>
      <phone>18241651300</phone>
      <email>wanghongyu790039663@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

